Thursday, January 17, 2019 1:54:11 AM
YIKES mega sales!
TC cnt 1d 1w 1m 6m
X
Filing Date
Trade Date
Ticker
Insider Name
Insider Title
Trade Type
Price
Qty
Owned
?Own
Value
1d
1w
1m
6m
D
2019-01-11 20:18:38
2019-01-10
AMRN Zakrzewski Joseph S Dir S - Sale+OE $16.98 -200,000 84,547 -70% -$3,396,390
D
2019-01-11 20:18:02
2019-01-10
AMRN Stack David M Dir S - Sale+OE $18.00 -125,504 0 -100% -$2,259,072
D
2019-01-11 20:17:19
2019-01-11
AMRN Kennedy Joseph T GC S - Sale+OE $18.92 -3,173 217,934 -1% -$60,033
D
2019-01-11 20:16:39
2019-01-09
AMRN Kalb Michael Wayne SVP, CFO S - Sale+OE $15.26 -200,000 17,486 -92% -$3,051,080
D
2019-01-11 20:16:04
2019-01-10
AMRN Ekman Lars Dir S - Sale+OE $17.28 -140,416 0 -100% -$2,426,489
DM
2019-01-02 19:54:29
2018-12-28
AMRN Zakrzewski Joseph S Dir S - Sale+OE $13.07 -526,500 84,547 -86% -$6,882,371
D
2019-01-02 19:53:07
2018-12-31
AMRN Kennedy Joseph T GC S - Sale+OE $13.49 -26,943 217,934 -11% -$363,547
D
2019-01-02 19:51:35
2018-12-31
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $13.51 -17,041 341,297 -5% -$230,212
D
2018-11-30 18:34:36
2018-11-30
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $17.79 -17,042 341,297 -5% -$303,174
D
2018-11-30 18:33:05
2018-11-30
AMRN Kennedy Joseph T GC S - Sale+OE $17.81 -23,306 217,934 -10% -$414,998
D
2018-11-14 18:02:13
2018-11-12
AMRN Thero John F Pres, CEO S - Sale+OE $19.07 -607,611 2,094,528 -22% -$11,587,896
D
2018-11-02 18:11:14
2018-10-31
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $20.74 -17,042 341,297 -5% -$353,454
D
2018-11-02 18:10:50
2018-10-31
AMRN Kennedy Joseph T GC S - Sale+OE $20.74 -23,307 217,934 -10% -$483,362
DM
2018-10-02 19:05:33
2018-09-28
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $16.13 -316,604 341,297 -48% -$5,105,589
D
2018-10-02 19:02:25
2018-10-01
AMRN Kennedy Joseph T GC S - Sale+OE $16.81 -50,249 217,934 -19% -$844,528
D
2018-09-26 20:54:54
2018-09-24
AMRN Zakrzewski Joseph S Dir S - Sale+OE $10.60 -500,000 226,047 -69% -$5,299,334
DM
2018-09-26 20:52:40
2018-09-24
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $11.10 -879,241 341,297 -72% -$9,760,024
D
2018-09-26 20:50:34
2018-09-24
AMRN Kennedy Joseph T GC S - Sale+OE $10.56 -1,079,706 217,934 -83% -$11,400,975
D
2018-09-26 20:47:14
2018-09-24
AMRN Kalb Michael Wayne SVP, CFO S - Sale+OE $10.42 -150,000 14,996 -91% -$1,562,751
D
2018-07-03 16:09:54
2018-07-02
AMRN Kennedy Joseph T GC S - Sale+OE $3.00 -26,942 18,434 -59% -$80,955
DM
2018-04-03 20:12:11
2018-04-02
AMRN Kennedy Joseph T GC S - Sale+OE $2.90 -26,942 18,434 -59% -$78,072
D
2018-02-02 20:25:13
2018-01-31
AMRN Kennedy Joseph T GC S - Sale+OE $3.73 -44,857 18,434 -71% -$167,388
D
2018-01-23 18:00:16
2018-01-23
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $4.41 -135,205 141,797 -49% -$596,430
M
2018-01-17 17:58:30
2018-01-12
AMRN Kennedy Joseph T GC S - Sale $4.10 -51,106 0 -100% -$209,450
D
2018-01-16 18:00:17
2018-01-11
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $4.40 -2,612 141,797 -2% -$11,493
D
2018-01-09 18:00:15
2018-01-05
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $4.40 -64,683 141,797 -31% -$284,631
D
2018-01-04 19:40:32
2018-01-02
AMRN Ketchum Steven B Chief Scientific Officer S - Sale+OE $4.25 -128,257 141,797 -47% -$545,092
2017-12-04 09:02:41
2017-11-30
AMRN Thero John F Pres, CEO P - Purchase $3.24 +10,000 1,135,003 +1% +$32,446
2017-10-06 19:22:03
2017-10-05
AMRN Ketchum Steven B Chief Scientific Officer S - Sale $3.48 -63,479 141,797 -31% -$221,199
DM
2017-07-03 19:20:40
2017-06-29
AMRN Kennedy Joseph T GC S - Sale+OE $4.00 -307,911 0 -100% -$1,230,933
Recent AMRN News
- Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual Europe • GlobeNewswire Inc. • 09/09/2024 11:30:00 AM
- Latest Research Highlighting VASCEPA®/VAZKEPA® (icosapent ethyl) REDUCE-IT® Subgroup Data and New Mechanistic Insights into Eicosapentaenoic Acid (EPA) to be Presented at European Society of Cardiology (ESC) Congress • GlobeNewswire Inc. • 08/22/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/05/2024 09:30:03 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:53 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/01/2024 08:54:46 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/31/2024 11:05:34 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 07/31/2024 11:05:26 AM
- Amarin Reports Second Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 07/31/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/29/2024 09:30:08 PM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Portugal • GlobeNewswire Inc. • 07/17/2024 08:15:00 PM
- Amarin to Report Second Quarter 2024 Financial Results and Host Conference Call on July 31, 2024 • GlobeNewswire Inc. • 07/17/2024 12:00:00 PM
- Amarin Partner EddingPharm Receives Regulatory Approval for VASCEPA® (Icosapent Ethyl) in Mainland China for Cardiovascular Risk Reduction (CVRR) • GlobeNewswire Inc. • 07/08/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/04/2024 11:30:10 AM
- Amarin Board of Directors Announces CEO Transition • GlobeNewswire Inc. • 06/04/2024 11:30:00 AM
- Amarin Receives National Reimbursement for VAZKEPA® (icosapent ethyl) in Greece and Announces Exclusive Marketing and Commercialization Agreement with Vianex S.A. • GlobeNewswire Inc. • 05/28/2024 12:15:23 PM
- Amarin to Present at H.C. Wainwright 2nd Annual BioConnect Investor Conference • GlobeNewswire Inc. • 05/06/2024 12:00:00 PM
- Amarin Reports First Quarter 2024 Business Update and Financial Results • GlobeNewswire Inc. • 05/01/2024 11:00:00 AM
- Amarin Applauds HealthyWomen’s Citizen’s Petition Urging FDA To Take Further Action On Fenofibrate Prescribing in Patients at Risk of Cardiovascular Event • GlobeNewswire Inc. • 04/24/2024 06:00:01 PM
- Amarin Announces Results of Annual General Meeting of Shareholders • GlobeNewswire Inc. • 04/22/2024 12:00:25 PM
- Amarin to Report First Quarter 2024 Financial Results and Host Conference Call on May 1, 2024 • GlobeNewswire Inc. • 04/15/2024 12:00:00 PM
- Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ACC.24 • GlobeNewswire Inc. • 04/08/2024 12:00:00 PM
- New REDUCE-IT® Analyses Show VASCEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • PR Newswire (Canada) • 04/08/2024 10:30:00 AM
- New REDUCE-IT® Analyses Show VASCEPA®/VAZKEPA® (Icosapent Ethyl) Benefit in High-Risk Cardiovascular Disease Patient Subgroups • GlobeNewswire Inc. • 04/06/2024 07:30:00 PM
- Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in Europe • GlobeNewswire Inc. • 04/03/2024 12:00:00 PM
- Research Evaluating Benefits of VASCEPA®/VAZKEPA® (icosapent ethyl) to be Presented at the American College of Cardiology’s (ACC) Annual Scientific Session & Expo • GlobeNewswire Inc. • 03/25/2024 12:00:00 PM
VHAI - Vocodia Partners with Leading Political Super PACs to Revolutionize Fundraising Efforts • VHAI • Sep 19, 2024 11:48 AM
Dear Cashmere Group Holding Co. AKA Swifty Global Signs Binding Letter of Intent to be Acquired by Signing Day Sports • DRCR • Sep 19, 2024 10:26 AM
HealthLynked Launches Virtual Urgent Care Through Partnership with Lyric Health. • HLYK • Sep 19, 2024 8:00 AM
Element79 Gold Corp. Appoints Kevin Arias as Advisor to the Board of Directors, Strengthening Strategic Leadership • ELMGF • Sep 18, 2024 10:29 AM
Mawson Finland Limited Further Expands the Known Mineralized Zones at Rajapalot: Palokas step-out drills 7 metres @ 9.1 g/t gold & 706 ppm cobalt • MFL • Sep 17, 2024 9:02 AM
PickleJar Announces Integration With OptCulture to Deliver Holistic Fan Experiences at Venue Point of Sale • PKLE • Sep 17, 2024 8:00 AM